The University of Texas MD Anderson Cancer Center: Research to Revenue

The University of Texas MD Anderson Cancer Center

Summit Venture Studio

Research to Revenue Report

Summit Venture Studio (SVS) Opportunities

SVS has identified 0 commercialization opportunities from The University of Texas MD Anderson Cancer Center and scored them based on our proprietary metrics and rubrics.

The SVS model is to identify the top 1% of commercialization opportunities and start companies around them.

Please connect with SVS if you would like to engage with us in our startup and investment efforts.

Return on Research (ROR) Analysis

Commercialization Revenue per Research Dollar

Top Universities by Return on Research (ROR)

ROI Ratio: Commercialization Revenue ÷ Research Funding

University Innovation Analysis

Total Innovation Scores by Institution

Top Universities by Innovation Score

180+ High Innovation

150-179 Strong Innovation

130-149 Moderate Innovation

100-129 Emerging Innovation

130+ total score considered high innovation impact

SVS Innovation Index

Proprietary Assessment of The University of Texas MD Anderson Cancer Center's Innovation Ecosystem
Score out of 100. Benchmark: Top 50 U.S. research institutions.
A score of 90/100 can be read "doing better than 90% of schools benchmarked"

Innovation Visibility

44/100

Definition: Media mentions, publication count, and global research visibility metrics

Startup Momentum

8/100

Definition: Growth in patents, funding, and startup formation

Ecosystem Strength

62/100

Definition: Tech transfer infrastructure and support systems

Innovation Legacy

A Timeline of Groundbreaking Discoveries

Innovation Timeline

Founded

1941

First Nobel

1989

First Patent

1985

First IPO

N/A

2022-2024

Cancer Immunotherapy Breakthrough

2025

Today

Notable Commercialization Outcomes

Nobel Prizes

1994

First Patent

Developed cancer drug compound

1994

Spin-off Company

Launched biotech startup

2000

Licensing Deal

Commercialized cancer diagnostic tool

2005

Clinical Trial

Tested novel immunotherapy

2010

Patent Granted

Innovative cancer treatment method

2015

Competitive Benchmarking

The University of Texas MD Anderson Cancer Center vs. Peer Research Universities

The University of Texas MD Anderson Cancer Center vs Peers Comparison

Metric	The University of Texas MD Anderson Cancer Center (FY2023)	Peer Average	Elite Average
Annual R&D Expenditure	$1,255M	$855M	$1,675M
New Inventions Disclosed	2	200	400
Startups Formed	3	7	10
Visibility Index	19	12	23
Licensing Revenue	$20M	$17M	$46M

Note: Peer Average = Median value among U.S. R1 research universities. Elite Average = Top 10 ranked U.S. research universities.

Emerging Opportunities

1. Precision Oncology AI Platform Revolutionizing Cancer Treatment Personalization

AI-driven platform tailors therapies to genetic cancer profiles, enhancing treatment efficacy and patient outcomes in a $200B oncology market.

2. Novel Immunotherapy Targets for Resistant Tumors

Innovative immunotherapy agents address treatment-resistant cancers, offering scalable solutions with potential to disrupt multi-billion-dollar oncology drug markets.

3. Advanced Radiotherapy Techniques Minimizing Healthy Tissue Damage

Cutting-edge radiotherapy tech improves targeting accuracy, reducing side effects and enabling broader adoption across global cancer treatment centers.

4. Liquid Biopsy Diagnostics for Early Cancer Detection

Non-invasive liquid biopsy tests enable early, accurate cancer diagnosis, facilitating timely interventions and capturing growing demand in diagnostic healthcare.

5. Nanoparticle Drug Delivery Systems Enhancing Chemotherapy Efficacy

Targeted nanoparticle carriers improve drug delivery precision, reducing toxicity and increasing treatment success rates in scalable cancer therapies.

6. Genomic Data Analytics Platform Accelerating Cancer Research

Big data analytics accelerate biomarker discovery and personalized medicine development, providing competitive advantage in precision oncology research and commercialization.